CIK 0001061983 · Large accelerated filer
CYTOKINETICS INC
Sign in to watch- Ticker
- CYTK
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 943291317
- Phone
- (650) 624-3000
- Business address
- 350 OYSTER POINT BOULEVARD, ., SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $12,208,275
- in 16 filings, $12.2M under 10b5-1 plans
Net −$12,208,275. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-08 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 26,886 | ||
| 2026-09-01 | PARSHALL B LYNNE Director | Sale 10b5-1 | −5,000 | $71.48 | $357K | 10,784 |
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +10,000 | $23.26 | $233K | 68,555 |
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −10,000 | $70.24 | $702K | 58,555 |
| 2026-08-31 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2026-08-31 | Blum Robert I President & CEO | Option exercise 10b5-1 | +7,500 | $10.60 | $80K | 385,320 |
| 2026-08-31 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $70.24 | $527K | 377,820 |
| 2026-08-31 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 164,245 | ||
| 2026-08-18 | Malik Fady Ibraham EVP Research & Development | Option exercise 10b5-1 | +3,500 | $7.80 | $27K | 157,402 |
| 2026-08-18 | Malik Fady Ibraham EVP Research & Development | Sale 10b5-1 | −3,500 | $75.82 | $265K | 153,902 |
| 2026-08-18 | Malik Fady Ibraham EVP Research & Development | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −3,500 | 30,386 | ||
| 2026-08-10 | Blum Robert I President & CEO | Option exercise 10b5-1 | +7,500 | $10.60 | $80K | 385,320 |
| 2026-08-10 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $76.76 | $576K | 377,820 |
| 2026-08-10 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 171,745 | ||
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise 10b5-1 | +14,000 | $23.26 | $326K | 72,555 |
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Sale 10b5-1 | −14,000 | $79.88 | $1.1M | 58,555 |
| 2026-07-30 | Callos Andrew EVP, Chief Commercial Officer | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −14,000 | 10,000 | ||
| 2026-07-27 | Blum Robert I President & CEO | Option exercise 10b5-1 | +7,500 | $10.60 | $80K | 385,320 |
| 2026-07-27 | Blum Robert I President & CEO | Sale 10b5-1 | −7,500 | $80.87 | $607K | 377,820 |
| 2026-07-27 | Blum Robert I President & CEO | Option exercise · Non-Qualified Stock Option (Right to Buy) 10b5-1 | −7,500 | 179,245 |
Page 3 of 22 · 429 trades